May 2025
-
Story Access to Healthcare
Why advocating for your MS is so important -
Press releaseNew Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipelineNATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients Pluvicto analysis and Scemblix ASC4START primary endpoint results…
-
Featured NewsVas Narasimhan named to 2025 TIME100 Health list
April 2025
-
Press releaseNovartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failureRegulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD), a severe renal diseaseLead asset for ADPKD…
-
Press releaseNovartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1Ad hoc announcement pursuant to Art. 53 LRNet sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto…
-
Press releaseNovartis setzt die starke Dynamik fort mit zweistelligem Umsatzwachstum, robusten Margensteigerungen und mehreren Zulassungen im ersten QuartalAd-hoc-Mitteilung gemäss Art. 53 KR Der Nettoumsatz wuchs um +15% (kWk1, +12% USD), das operative Kernergebnis1 verbesserte sich um +27% (kWk, +23% USD)Das Umsatzwachstum beruhte auf…
-
Featured NewsEurope talks health sovereignty — now it must deliver
-
Story People and Culture
Science in Motion: Autumn and Sabrina's Noteworthy Novartis Adventure -
Press releaseNovartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)Ad hoc announcement pursuant to Art. 53 LR Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation…
March 2025
-
Press releaseNovartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of NovartisAfter nearly seven years as a member of the Executive Committee of Novartis (ECN), Klaus Moosmayer will pursue his next chapter of leadership outside of NovartisKaren Hale to drive the next phase of…
-
Press releaseFDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancerAd hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to be used after one androgen receptor pathway inhibitor (ARPI)…
-
Press releaseNovartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosisLong-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis (RMS) patients…